#SLGL

StockTitan

@stocktitan.net

2 months ago

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease Sol-Gel (NASDAQ: SLGL) announced results after unblinding a vehicle-controlled Phase 1b proof-of-concept study of SGT-210 in Darier disease on Dec 17, 2025. The company reported that the study did not show differentiation between SGT-210 and vehicle on efficacy assessments, and will not advance SGT-210 to the next development stage in Darier disease. The company said it plans to pursue very small, low-cost feasibility studies of SGT-210 in other indications with stronger mechanistic rationale. Sol-Gel also reiterated its ongoing focus on completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparatory activities for a potential Phase 3 program in high-frequency BCC, contingent on Gorlin Phase 3 success.

#SLGL Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

www.stocktitan.net/news/SLGL/sol-gel-provid...

StockTitan

@stocktitan.net

3 months ago

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY Sol-Gel signed an additional agreement with

#SLGL Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SLGL/sol-gel-report...

StockTitan

@stocktitan.net

6 months ago

$11M Milestone Potential: Sol-Gel's EPSOLAY Wins Canadian Approval, Global Expansion Plans Target $10M EBITDA Sol-Gel's EPSOLAY approved by Health Canada for adult rosacea treatment. Partnership with Searchlight Pharma includes up to $11M in milestones. Global launches planned for 2027-2028.

#SLGL Sol-Gel Announces Health Canada Approval of EPSOLAY®

www.stocktitan.net/news/SLGL/sol-gel-announ...

StockTitan

@stocktitan.net

7 months ago

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2025 financial results and significant corporate updates. The company announced total revenue of $17.2 million, primarily from a $16 million product sale agreement with Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. The quarter resulted in a net income of $11.6 million, or $4.17 per share.Key developments include completion of patient enrollment for the Phase-3 trial of SGT-610 for Gorlin Syndrome, with top-line results expected in Q4 2026. The company continues its Phase-1b trial of SGT-210 for Darier disease. Sol-Gel implemented a 10-for-1 reverse share split to maintain Nasdaq listing. The company's cash position of $24.2 million is expected to extend runway into Q1 2027.

#SLGL Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SLGL/sol-gel-report...

StockTitan

@stocktitan.net

9 months ago

Sol-Gel Reports First Quarter 2025 Results Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31 st , 2025 Total revenue

#SLGL Sol-Gel Reports First Quarter 2025 Results

www.stocktitan.net/news/SLGL/sol-gel-report...

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

Small-cap stocks with strong volume gains, Tue May 6th - #TOPP #VSA #TDUP #SLGL #RGC #MRIN #HTRX #GLMD #FARO #EVGO #DHC #AORT #EQV #CCLD #BTMD #IHS #IPI #VCSA #FOXO #ADN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Market Wire News

@marketwirenews.com

10 months ago

Just In: ( NASDAQ: #SLGL ) SLGL announced stock split 1-10

StockTitan

@stocktitan.net

10 months ago

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. Sol-Gel Technologies (NASDAQ: SLGL) has entered into a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO. The deal will provide Sol-Gel with $16 million in two installments during 2025, extending their cash runway into Q1 2027.The company will focus on developing SGT-610, a potential first-ever preventative treatment for basal cell carcinomas in Gorlin syndrome patients, with an estimated U.S. market potential of $400-500 million annually. The Phase III trial has achieved 80% patient enrollment, with top-line results expected in Q4 2026.As of March 31, 2025, Sol-Gel reported $16.9 million in cash and equivalents. The company is also advancing SGT-210, a treatment for Darier disease with a market potential of $200-300 million, with 50% of patients having completed the Phase 1b trial.

#SLGL Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

www.stocktitan.net/news/SLGL/sol-gel-and-ma...

StockTitan

@stocktitan.net

1 year ago

#SLGL Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

www.stocktitan.net/news/SLGL/sol-gel-announ...

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #SLGL ) Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

#SLGL Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/SLGL/sol-gel-report...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #SLGL ) Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

#StockMarket #News